|
Market Closed -
Euronext Bruxelles
01:55:00 26/09/26 am AEST
|
After hours 04:34:48 am | |||
| 214.40 EUR | +1.18% |
|
214.20 | -0.09% |
| 25/09 | BofA Reaffirms UCB at Buy Amid 'Very Confident' Outlook for Psoriasis Drug | MT |
| 24/09 | BofA Securities Keeps UCB at Buy | MT |
Company Valuation: UCB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,947 | 13,973 | 14,969 | 36,464 | 45,333 | 40,401 | - | - |
| Change | - | -26.25% | 7.12% | 143.6% | 24.32% | -10.88% | - | - |
| Enterprise Value (EV) 1 | 19,807 | 15,973 | 17,146 | 37,918 | 45,326 | 40,800 | 38,675 | 36,142 |
| Change | - | -19.36% | 7.34% | 121.15% | 19.54% | -9.98% | -5.21% | -6.55% |
| P/E | 17.9x | 33.4x | 44.8x | 34.3x | 29.1x | 21.2x | 17.6x | 14.5x |
| PBR | 2.32x | 1.58x | 1.67x | 3.64x | 4.18x | 3.35x | 2.93x | 2.43x |
| PEG | - | -0.6x | -2.2x | 0x | 0.6x | 1x | 0.9x | 0.7x |
| Capitalization / Revenue | 3.28x | 2.53x | 2.85x | 5.93x | 5.86x | 4.65x | 4.2x | 3.78x |
| EV / Revenue | 3.43x | 2.9x | 3.26x | 6.16x | 5.86x | 4.7x | 4.02x | 3.38x |
| EV / EBITDA | 12.1x | 12.7x | 12.7x | 25.7x | 17.2x | 13.4x | 10.7x | 8.53x |
| EV / EBIT | 15x | 23.7x | 26.1x | 45.4x | 22.6x | 16.6x | 13x | 9.97x |
| EV / FCF | 15.6x | 18.4x | 38.5x | 41.2x | 24.6x | 21.4x | 14.8x | 11.7x |
| FCF Yield | 6.42% | 5.43% | 2.6% | 2.43% | 4.06% | 4.68% | 6.75% | 8.52% |
| Dividend per Share 2 | 1.3 | 1.33 | 1.36 | 1.39 | 1.45 | 1.457 | 1.502 | 1.534 |
| Rate of return | 1.3% | 1.81% | 1.72% | 0.72% | 0.61% | 0.69% | 0.71% | 0.72% |
| EPS 2 | 5.6 | 2.2 | 1.76 | 5.61 | 8.2 | 9.999 | 12.01 | 14.61 |
| Distribution rate | 23.2% | 60.5% | 77.3% | 24.8% | 17.7% | 14.6% | 12.5% | 10.5% |
| Net sales 1 | 5,777 | 5,517 | 5,252 | 6,152 | 7,741 | 8,682 | 9,622 | 10,686 |
| EBITDA 1 | 1,641 | 1,260 | 1,349 | 1,476 | 2,636 | 3,053 | 3,621 | 4,239 |
| EBIT 1 | 1,318 | 675 | 657 | 836 | 2,009 | 2,459 | 2,974 | 3,624 |
| Net income 1 | 1,058 | 418 | 343 | 1,065 | 1,558 | 1,928 | 2,296 | 2,786 |
| Net Debt 1 | 860 | 2,000 | 2,177 | 1,454 | -7 | 399 | -1,727 | -4,259 |
| Reference price 2 | 100.35 | 73.56 | 78.90 | 192.20 | 238.60 | 211.90 | 211.90 | 211.90 |
| Nbr of stocks (in thousands) | 188,812 | 189,959 | 189,721 | 189,720 | 189,996 | 190,663 | - | - |
| Announcement Date | 24/2/22 | 22/2/23 | 28/2/24 | 27/2/25 | 24/2/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.17x | 4.69x | 13.35x | 0.69% | 45.93B | |
| 18.14x | 4.26x | 10.04x | 0.49% | 79.49B | |
| -23.24x | 35.29x | -22.91x | -.--% | 77.78B | |
| 20.69x | 4.4x | 13.62x | 2.39% | 60.16B | |
| 33.28x | 11.32x | 21.7x | -.--% | 46.14B | |
| 36.92x | 3.68x | 13.78x | -.--% | 33.45B | |
| 55.53x | 3.53x | 27.38x | -.--% | 25.22B | |
| 63.4x | 7.07x | 42.3x | -.--% | 22.15B | |
| 22.85x | 4.91x | 12.79x | -.--% | 15.25B | |
| -24.55x | 13.71x | -37x | -.--% | 12.96B | |
| Average | 22.42x | 9.29x | 9.50x | 0.36% | 41.85B | |
| Weighted average by Cap. | 17.82x | 11.25x | 7.78x | 0.51% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- UCB Stock
- Valuation UCB
Select your edition
All financial news and data tailored to specific country editions
